EC Number   |
Natural Substrates |
|---|
    5.3.99.4 | (5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate |
i.e. prostaglandin H2 |
| 5.3.99.4 | (5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate |
- |
| 5.3.99.4 | Prostaglandin H2 |
- |
| 5.3.99.4 | Prostaglandin H2 |
in vivo, this reaction is coupled to a previous one, where arachidonic acid is converted by cyclooxygenase and yields the substrate PGH2 |
| 5.3.99.4 | Prostaglandin H2 |
produces prostaglandin I2 which has opposite actions on platelet aggregatory and vasoconstrictive properties |
| 5.3.99.4 | Prostaglandin H2 |
formation of prostaglandin I2 which is a powerful vasodilator and the most potent naturally occuring inhibitor of platlet aggregation. An imbalance in the ratio of prostaglandin I2 to thromboxane A2, a compound that has opposite biological properties may reflect some of the changes occuring in various pathological situations including thrombosis and ischemia |
| 5.3.99.4 | Prostaglandin H2 |
formation of prostaglandin I2, which is a powerful vasodilator and the most potent natural occuring inhibitor of platelet aggregation |
